The distinctive features of valencian university didactics are the transmission of information with little knowledge management by the student and the teacher. The objective was to renew the didactics through classroom projects in the management of knowledge. The methodology consisted of the practice of the training partner, focused on personalized work, research action and collaborative work. The results are the assessment of metacognition, the importance of individual talent, and the socialization of knowledge in learning brigades. We conclude that the classroom project in the classroom is a didactic strategy that allows for discerning levels of learning, from individual work, learning in brigades and socialization of knowledge.

The distinctive features of valencian university didactics are the transmission of information with little knowledge management by the student and the teacher. The objective was to renew the didactics through classroom projects in the management of knowledge. The methodology consisted of the practice of the training partner, focused on personalized work, research action and collaborative work. The results are the assessment of metacognition, the importance of individual talent, and the socialization of knowledge in learning brigades. We conclude that the classroom project in the classroom is a didactic strategy that allows for discerning levels of learning, from individual work, learning in brigades and socialization of knowledge.

Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor mutant (EGFRm) advanced non-small cell lung cancer (NSCLC). Combining TKIs with an angiogenesis inhibitor has shown promise in pre-clinical studies. A systematic search of clinical trials found that combining erlotinib (a first-generation TKI) with bevacizumab or ramucirumab (angiogenesis inhibitors) improved progression-free survival (PFS) in EGFRm advanced NSCLC patients compared to TKI alone. However, no significant benefit in overall survival (OS) was observed in trials. Similar efficacy was seen in patients with specific EGFR mutations. Third generation TKIs were used as second-line therapy for patients with the T790M mutation. The combination treatment was associated with a higher incidence of severe adverse events. Overall, combining erlotinib or another TKI with an angiogenesis inhib...